TuHURA Biosciences remains a high-risk investment due to severe cash constraints and imminent dilution risk despite progress in its immunotherapy pipeline. HURA's phase 3 trial for IFx-Hu2.0 in ...
Solid Biosciences is approaching key catalysts in DMD gene therapy, with SGT-003 showing promising early safety and efficacy signals. The evolving DMD landscape, especially safety concerns with ...
Twist Bioscience (NasdaqGS:TWST) raised its full year revenue guidance, reflecting updated expectations for its business in synthetic DNA and protein solutions. The company highlighted strong demand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results